AtaiBeckley Inc. 8-K

What Happened
AtaiBeckley Inc. announced on July 15, 2026 that it entered into a definitive Agreement and Plan of Merger with Eli Lilly and Company and a Lilly subsidiary (Albali Acquisition Corp.). Under the agreement, Merger Sub will merge into AtaiBeckley and AtaiBeckley will become a wholly owned subsidiary of Eli Lilly if closing conditions are met. The AtaiBeckley board unanimously approved the Merger Agreement. The announced merger consideration is $6.75 in cash per share plus one contingent value right (CVR) per share that can pay up to $2.50 additional per share if specified clinical and regulatory milestones are met.

Key Details

• Cash and milestone structure: $6.75 cash per share at closing plus one CVR per share; each CVR can pay up to $2.50 total upon achieving milestones (up to $1.00 for Phase 3 initiation of VLS‑01 before the 4th anniversary; $0.50 for U.S. approval and DEA rescheduling of BPL‑003 before the 5th anniversary; $1.00 for U.S. approval and DEA rescheduling of VLS‑01 before the 7th anniversary).
• Equity treatment: In-the-money stock options (exercise price < $6.75) will be cashed out (excess value × shares) and receive one CVR per underlying share; out-of‑the‑money options (≥ $6.75) are cancelled for no consideration; unvested RSUs will be cashed out at $6.75 per share plus one CVR per share. Pre-funded warrants remain exercisable into the same merger consideration.
• Approvals & timing: Closing requires majority stockholder approval, expiration/clearance under HSR and other antitrust reviews; outside date is six months (auto-extendable to nine months for certain regulatory conditions).
• Other commercial terms: Voting/support agreements were signed by the company’s directors, executive officers and Apeiron Investment Group, Ltd.; a potential termination fee of $104.3 million is payable by AtaiBeckley under certain circumstances (e.g., to accept a superior proposal subject to agreement terms).

Why It Matters
This is a definitive acquisition agreement that would take AtaiBeckley private as a Lilly subsidiary and deliver immediate cash value ($6.75/share) to public shareholders at closing, with possible additional milestone payments through CVRs tied to specific drug-development and regulatory achievements. Key next steps for investors are the upcoming stockholder vote and regulatory clearances; equity holders should also note how company option holders and RSU holders will be cashed out or cancelled per the agreement.